[go: up one dir, main page]

FR2939135B1 - Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique - Google Patents

Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique

Info

Publication number
FR2939135B1
FR2939135B1 FR0858207A FR0858207A FR2939135B1 FR 2939135 B1 FR2939135 B1 FR 2939135B1 FR 0858207 A FR0858207 A FR 0858207A FR 0858207 A FR0858207 A FR 0858207A FR 2939135 B1 FR2939135 B1 FR 2939135B1
Authority
FR
France
Prior art keywords
azacycloalkyl
benzene
novel
preparation
cosmetics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0858207A
Other languages
English (en)
Other versions
FR2939135A1 (fr
Inventor
Jean Guy Boiteau
Karine Bouquet
Sandrine Talano
Barbuis Corinne Millois
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0858207A priority Critical patent/FR2939135B1/fr
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to RU2011127126/04A priority patent/RU2499794C2/ru
Priority to JP2011539019A priority patent/JP5346092B2/ja
Priority to ES09763959.5T priority patent/ES2536072T3/es
Priority to US13/131,363 priority patent/US8299259B2/en
Priority to BRPI0916480A priority patent/BRPI0916480B1/pt
Priority to PCT/EP2009/066268 priority patent/WO2010063774A1/fr
Priority to MX2011005478A priority patent/MX2011005478A/es
Priority to CN200980147097.6A priority patent/CN102224139B/zh
Priority to AU2009324081A priority patent/AU2009324081B2/en
Priority to EP09763959.5A priority patent/EP2373620B1/fr
Priority to ARP090104648A priority patent/AR074453A1/es
Priority to CA2742709A priority patent/CA2742709C/fr
Priority to EP15154368.3A priority patent/EP2907804A1/fr
Priority to KR1020117015286A priority patent/KR101308808B1/ko
Priority to CN201410539219.9A priority patent/CN104666299A/zh
Publication of FR2939135A1 publication Critical patent/FR2939135A1/fr
Application granted granted Critical
Publication of FR2939135B1 publication Critical patent/FR2939135B1/fr
Priority to US13/611,546 priority patent/US8697726B2/en
Priority to US14/200,954 priority patent/US20140187532A1/en
Priority to US14/469,199 priority patent/US8993596B2/en
Priority to US14/659,800 priority patent/US20150191451A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La présente invention se rapporte à de nouveaux composés 4-(azacycloalkyl)-benzene-1,3-diol répondant à la formule générale (l) suivante : aux compositions les contenant, à leur procédé de préparation et à leur utilisation dans des compositions pharmaceutiques ou cosmétiques destinées au traitement ou à la prévention des désordres pigmentaires.
FR0858207A 2008-12-02 2008-12-02 Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique Expired - Fee Related FR2939135B1 (fr)

Priority Applications (20)

Application Number Priority Date Filing Date Title
FR0858207A FR2939135B1 (fr) 2008-12-02 2008-12-02 Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
ARP090104648A AR074453A1 (es) 2008-12-02 2009-12-02 Compuestos 4-(azacicloalquil ) benceno-1,3-diol, como inhibidores de la tirosinasa y su uso en medicina humana y tambien en cosmetica
ES09763959.5T ES2536072T3 (es) 2008-12-02 2009-12-02 Nuevos compuestos 4-(azacicloalquil)benceno-1,3-diol como inhibidores de tirosinasa, proceso para la preparación de éstos y uso de éstos en medicina humana y en cosméticos
US13/131,363 US8299259B2 (en) 2008-12-02 2009-12-02 4-(azacycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and in cosmetics
BRPI0916480A BRPI0916480B1 (pt) 2008-12-02 2009-12-02 composto de fórmula geral (i) e uso de pelo menos um composto
PCT/EP2009/066268 WO2010063774A1 (fr) 2008-12-02 2009-12-02 Nouveaux composés de 4- (azacycloalkyl) benzene-1, 3-diol utilisés comme inhibiteurs de la tyrosinase, leur procédé de préparation et leur utilisation en médicine humaine et dans les cosmétiques
JP2011539019A JP5346092B2 (ja) 2008-12-02 2009-12-02 チロシナーゼ阻害剤としての新規の４−（アザシクロアルキル）ベンゼン−１，３−ジオール化合物、それ自身を調製するプロセス、ならびに、ヒト医薬および化粧品におけるそれ自身の使用
CN200980147097.6A CN102224139B (zh) 2008-12-02 2009-12-02 作为酪氨酸酶抑制剂的4-(氮杂环烷基)苯-1，3-二酚化合物，其制备方法及其在人类药物及化妆品中的应用
AU2009324081A AU2009324081B2 (en) 2008-12-02 2009-12-02 Novel 4-(azacycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and in cosmetics
EP09763959.5A EP2373620B1 (fr) 2008-12-02 2009-12-02 Nouveaux composés de 4- (azacycloalkyl) benzene-1, 3-diol utilisés comme inhibiteurs de la tyrosinase, leur procédé de préparation et leur utilisation en médicine humaine et dans les cosmétiques
RU2011127126/04A RU2499794C2 (ru) 2008-12-02 2009-12-02 Новые 4-(азациклоалкил)бензол-1,3-диоловые соединения в качестве ингибиторов тирозиназ, способ их получения и их применение в лечении человека и в косметических средствах
MX2011005478A MX2011005478A (es) 2008-12-02 2009-12-02 Novedosos compuestos de 4-(azacicloalquil)benceno-1,3-diol como inhibidores de tirosinasa, procedimiento para la preparacion de los mismos y uso de los mismos en medicina humana y en cosmeticos.
CA2742709A CA2742709C (fr) 2008-12-02 2009-12-02 Nouveaux composes de 4- (azacycloalkyl) benzene-1, 3-diol utilises comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medicine humaine et dansles cosmetiques
KR1020117015286A KR101308808B1 (ko) 2008-12-02 2009-12-02 타이로시나아제 억제제로서의 신규 ４-(아자시클로알킬)벤젠-１,３-디올 화합물, 이의 제조 방법 및 인간 의약 및 화장품에서의 이의 용도
CN201410539219.9A CN104666299A (zh) 2008-12-02 2009-12-02 作为酪氨酸酶抑制剂的4-(氮杂环烷基)苯-1,3-二酚化合物,其制备方法和应用
EP15154368.3A EP2907804A1 (fr) 2008-12-02 2009-12-02 Nouveaux composés 4-(azacycloalkyl)benzène-1,3-diol en tant qu'inhibiteurs de la tyrosinase, leur procédé de préparation et leur utilisation en médecine humaine et en cosmétique
US13/611,546 US8697726B2 (en) 2008-12-02 2012-09-12 4-(azacycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and in cosmetics
US14/200,954 US20140187532A1 (en) 2008-12-02 2014-03-07 4-(azacycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and in cosmetics
US14/469,199 US8993596B2 (en) 2008-12-02 2014-08-29 4-(azacycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and in cosmetics
US14/659,800 US20150191451A1 (en) 2008-12-02 2015-03-17 4-(azacycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and in cosmetics

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0858207A FR2939135B1 (fr) 2008-12-02 2008-12-02 Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique

Publications (2)

Publication Number Publication Date
FR2939135A1 FR2939135A1 (fr) 2010-06-04
FR2939135B1 true FR2939135B1 (fr) 2010-12-03

Family

ID=40852143

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0858207A Expired - Fee Related FR2939135B1 (fr) 2008-12-02 2008-12-02 Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique

Country Status (14)

Country Link
US (5) US8299259B2 (fr)
EP (2) EP2373620B1 (fr)
JP (1) JP5346092B2 (fr)
KR (1) KR101308808B1 (fr)
CN (2) CN104666299A (fr)
AR (1) AR074453A1 (fr)
AU (1) AU2009324081B2 (fr)
BR (1) BRPI0916480B1 (fr)
CA (1) CA2742709C (fr)
ES (1) ES2536072T3 (fr)
FR (1) FR2939135B1 (fr)
MX (1) MX2011005478A (fr)
RU (1) RU2499794C2 (fr)
WO (1) WO2010063774A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2939135B1 (fr) * 2008-12-02 2010-12-03 Galderma Res & Dev Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
FR2953834B1 (fr) * 2009-12-10 2012-01-13 Galderma Res & Dev Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
FR3000065A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes
BR112015019208A2 (pt) 2013-02-14 2017-07-18 Galderma Res & Dev processo de síntese
KR20160093069A (ko) 2013-12-04 2016-08-05 갈데르마 리써어치 앤드 디벨로프먼트 레티노이드를 바람직하게 포함하는 지질 마이크로캡슐, 및 이를 포함하는 조성물, 이의 제조 방법, 및 피부과에 있어서의 이의 용도
JP6492531B2 (ja) * 2014-10-27 2019-04-03 セイコーエプソン株式会社 表示装置、及び、表示装置の制御方法
EP3302421B1 (fr) * 2015-05-29 2021-07-07 Galderma Research & Development Compositions comprenant au moins un principe actif disperse et des microcapsules lipidiques
EP3324924B1 (fr) * 2015-07-23 2019-08-21 DSM IP Assets B.V. Nouveaux inhibiteurs selectifs de la 11-beta-hydroxysteroide dehydrogenase de type 1
DK3668853T3 (da) * 2017-08-16 2021-12-06 Glaxosmithkline Ip Dev Ltd Nye forbindelser
JP7346425B2 (ja) * 2018-01-11 2023-09-19 セントラス セラピューティクス 疾患を治療するためのジヒドロセラミドデサチュラーゼ阻害剤
CN109020996B (zh) * 2018-09-03 2020-09-11 常州工程职业技术学院 一种具有光活性的杂多环化合物及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0651619B2 (ja) 1988-05-09 1994-07-06 株式会社クラレ 美白剤
FR2704428B1 (fr) 1993-04-29 1995-06-09 Oreal Utilisation de dérivés de la résorcine substitués en position(s) 4, 4 et 5 ou 4 et 6 dans des compositions cosmétiques ou dermopharmaceutiques à action dépigmentante.
BR9803596A (pt) 1997-09-23 2000-04-25 Pfizer Prod Inc Derivados do resorcinol.
IL144850A0 (en) * 1999-03-22 2002-06-30 Pfizer Resorcinol derivatives
HN2000000033A (es) * 1999-03-22 2001-02-02 Pfizer Prod Inc Composicion de resorcinol
EP1317425B1 (fr) * 2000-09-11 2004-11-03 Pfizer Products Inc. Derives de resorcinol
JP3950046B2 (ja) * 2000-09-21 2007-07-25 ファイザー・プロダクツ・インク レゾルシノール誘導体
US6852310B2 (en) 2002-08-23 2005-02-08 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Skin lightening agents, compositions and methods
US6875425B2 (en) 2002-12-12 2005-04-05 Unilever Home & Personal Care Usa Skin lightening agents, compositions and methods
AU2004209505B2 (en) * 2003-02-10 2009-07-23 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
CA2512886A1 (fr) * 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands modulant des recepteurs du type lxr
US7300646B2 (en) 2004-02-27 2007-11-27 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin lightening agents, compositions and methods
US20060210497A1 (en) 2005-03-18 2006-09-21 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Novel resorcinol derivatives
US20060210498A1 (en) 2005-03-18 2006-09-21 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Novel resorcinol derivatives for skin
DE102005061657A1 (de) * 2005-06-16 2006-12-28 Merck Patent Gmbh Verwendung von substituierten Piperazin- und Morpholinderivaten
FR2937972B1 (fr) * 2008-11-04 2013-03-29 Galderma Res & Dev Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
FR2937973B1 (fr) * 2008-11-04 2010-11-05 Galderma Res & Dev Modulateurs des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
FR2939135B1 (fr) * 2008-12-02 2010-12-03 Galderma Res & Dev Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
FR2939136B1 (fr) * 2008-12-02 2010-12-03 Galderma Res & Dev Nouveaux composes 4-(heterocycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique

Also Published As

Publication number Publication date
KR20110091803A (ko) 2011-08-12
EP2373620A1 (fr) 2011-10-12
JP2012510504A (ja) 2012-05-10
US20140187532A1 (en) 2014-07-03
JP5346092B2 (ja) 2013-11-20
FR2939135A1 (fr) 2010-06-04
ES2536072T3 (es) 2015-05-20
BRPI0916480A2 (pt) 2016-06-14
US8299259B2 (en) 2012-10-30
CN102224139A (zh) 2011-10-19
US8993596B2 (en) 2015-03-31
US8697726B2 (en) 2014-04-15
KR101308808B1 (ko) 2013-09-13
US20140371197A1 (en) 2014-12-18
MX2011005478A (es) 2011-06-20
BRPI0916480B1 (pt) 2019-01-15
EP2373620B1 (fr) 2015-03-18
EP2907804A1 (fr) 2015-08-19
WO2010063774A1 (fr) 2010-06-10
CA2742709C (fr) 2013-10-08
US20130023516A1 (en) 2013-01-24
CN104666299A (zh) 2015-06-03
RU2011127126A (ru) 2013-01-10
US20150191451A1 (en) 2015-07-09
RU2499794C2 (ru) 2013-11-27
AR074453A1 (es) 2011-01-19
AU2009324081A1 (en) 2010-06-10
CA2742709A1 (fr) 2010-06-10
CN102224139B (zh) 2014-11-19
AU2009324081B2 (en) 2012-10-11
US20110311466A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
FR2939135B1 (fr) Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
MA38099A1 (fr) Des nouveaux composes triazolopyrazines substitues inhibiteurs des brd4
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
MA34474B1 (fr) Agonistes de gpr40
MA31841B1 (fr) Modulateurs du gpr40 à biphényle substitué
MA31845B1 (fr) Pipéridino-dihydrothiénopyrimidines substituées
FR2928270B1 (fr) Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
TN2012000074A1 (fr) Derives de thieno [2, 3-b] pyridine servant d'inhibiteurs de replication virale
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA35874B1 (fr) Dérivés d'amide cycliques à utiliser en tant qu'inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase et utilisations de ceux-ci
MA31094B1 (fr) Utilisation de dérivés de pyranone-acide substituée pour le traitement du syndrome métabolique
FR2970971B1 (fr) Utilisation d'au moins un co-produit de l'industrie du raffinage des huiles vegetales pour obtenir un insaponifiable total purifie d'huile vegetale.
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1
FR2952372B1 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
FR2939136B1 (fr) Nouveaux composes 4-(heterocycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
MA33742B1 (fr) Co-cristaux de tramadol et de coxibs
TN2012000285A1 (fr) NOUVEAUX DERIVES D' (HETEROCYCLE-PIPERIDINE CONDENSEE)-(PIPERAZINYL)-1-ALCANONE OU D' (HETEROCYCLE-PYRROLIDINE CONDENSEE)-(PIPERAZINYL)-1-ALCANONE ET LEUR UTILISATION COMME INHIBITEURS DE p75
MA32810B1 (fr) Ester de diol et d'acide gras polyinsature comme agent anti-acne
FR2947270B1 (fr) Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
WO2009117283A3 (fr) Modulateurs allostériques positifs du récepteur m1 de la quinolizidine
MA33979B1 (fr) Piperazines en tant qu'agents antipaludiques
FR2968662B1 (fr) Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

ST Notification of lapse

Effective date: 20230808